Publications by authors named "Luciana V B Casadio"
Article Synopsis
- * In group 1 (44 patients with acute hepatitis A), 4% tested positive for HEV IgM and 14.5% for IgG, while in group 2 (47 patients with non-A-C AH), these rates were 4.3% for IgM and 14.9% for IgG; only one sample from group 2 tested positive for HEV RNA.
- * The findings suggest HEV should be considered in non-A-C acute hepatitis cases, particularly as one patient with HEV recently traveled to a high-serop
Article Synopsis
- - A healthcare worker contracted monkeypox virus (MPXV) from a patient due to a needlestick injury, leading to a lesion forming five days later.
- - The worker tested positive for MPXV in their blood before showing severe symptoms, and the virus was still detectable 19 days after symptoms began.
- - Implementing postexposure prophylaxis could help prevent the spread of MPXV through bloodborne routes in similar cases.
Article Synopsis
- Two new cases of Sabiá virus (SABV) infection were diagnosed in Brazil, marking the first instances in over 20 years.
- The infected patients exhibited severe symptoms, including hepatitis and neurological issues, leading to their deaths, with unique histopathological features observed in autopsies.
- Despite the possibility of transmission in healthcare settings, contact tracing showed no additional infections among hospital staff and contacts, highlighting the rarity of this virus.
Article Synopsis
- * From 2016 to 2018, an outbreak in 22 European countries reported 4,475 cases, with a significant number among men who have sex with men (MSM), which later spread to cities like São Paulo in Brazil.
- * In a study of 51 hepatitis A cases in São Paulo, a high percentage were male and many identified as MSM; the majority of HAV strains were similar to those from the earlier European outbreaks, highlighting the need for increased vaccination efforts in high-risk groups.
Article Synopsis
- A multicenter clinical trial was launched in January 2018 to test the effectiveness of sofosbuvir on yellow fever (YF) during a significant outbreak in Brazil.
- Despite the urgent need due to rising cases, the approval process faced many regulatory and ethical challenges that slowed progress.
- By April 2018, only 29 out of a target of 90 patients were enrolled, indicating a need for better preparedness for rapid research in future outbreak situations.
Introduction: An ongoing outbreak of yellow fever (YF) has been reported in Brazil with 1261 confirmed cases and 409 deaths since July 2017. To date, there is no specific treatment available for YF. Recently published papers describing in vitro and animal models suggest a potential effect of antiviral drugs (approved for the treatment of hepatitis virus) against flaviviruses, including YF.
View Article and Find Full Text PDFArticle Synopsis
- - Yellow fever (YF) remains a significant health threat despite effective vaccines, as seen in a 2018 outbreak in São Paulo, Brazil, in areas previously free from the virus.
- - This study examined 62 severe YF cases, identifying key clinical and laboratory factors linked to outcomes, such as liver enzyme levels and other biomarkers.
- - Findings indicate that lipase and factor V are strong predictors of mortality in YF patients, highlighting severe organ damage and the risks of liver failure in critical cases.